Brokerages expect Voyager Therapeutics Inc (NASDAQ:VYGR) to report $5.05 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Voyager Therapeutics’ earnings, with estimates ranging from $1.50 million to $6.71 million. Voyager Therapeutics posted sales of $2.36 million during the same quarter last year, which suggests a positive year-over-year growth rate of 114%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $5.05 million for the current year, with estimates ranging from $4.70 million to $10.49 million. For the next fiscal year, analysts forecast that the business will report sales of $13.24 million per share, with estimates ranging from $5.00 million to $32.20 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Voyager Therapeutics.
Several analysts have weighed in on VYGR shares. Wedbush reaffirmed a “positive” rating and set a $31.00 target price (down previously from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Canaccord Genuity started coverage on Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Cowen reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Finally, ValuEngine cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $26.90.
In other news, insider Bernard Ravina sold 10,980 shares of Voyager Therapeutics stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total transaction of $223,223.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 21,960 shares of company stock worth $370,850. 8.00% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in shares of Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after acquiring an additional 4,343 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Voyager Therapeutics in the 2nd quarter worth $143,000. Rhumbline Advisers grew its holdings in shares of Voyager Therapeutics by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after acquiring an additional 4,144 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Voyager Therapeutics by 8.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares during the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of Voyager Therapeutics by 24.7% in the 2nd quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock worth $230,000 after acquiring an additional 5,081 shares during the last quarter. Institutional investors and hedge funds own 35.97% of the company’s stock.
WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/06/brokerages-expect-voyager-therapeutics-inc-vygr-will-post-quarterly-sales-of-5-05-million.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.